Clinic Roundup

BioWorld Today

June 28, 2007

Isotechnika Inc., of Edmonton, Alberta, completed patient enrollment in its Phase IIb trial assessing ISA247 for the prevention of kidney graft rejection following transplantation.

Of the 332 patients enrolled, 148 patients already completed the required six months of treatment.

The company expects to have the last patient complete the six months of active treatment before the end of the year.

Health Canada has granted a no objection letter allowing patients who already have completed 12 months of ISA247 treatment to continue therapy through to commercialization of the drug.